Barclays Maintains Overweight on Xylem, Lowers Price Target to $139
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst William Grippin maintains Xylem (NYSE:XYL) with a Overweight and lowers the price target from $159 to $139.
Barclays analyst William Grippin maintains Xylem (NYSE:XYL) with a Overweight and lowers the price target from $159 to $139.